Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Abnormal Tc-99m MAA accumulation.

A Hiltz1, S Iles

  • 1Department of Pharmaceutical Services, Victoria General Hospital, Halifax, Nova Scotia, Canada.

Clinical Nuclear Medicine
|October 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Women's views about breast cancer prevention at mammography screening units and well women's clinics.

Current oncology (Toronto, Ont.)·2020
Same author

Monoclonal-antibodies to human breast-cancer associated antigens.

International journal of oncology·2011
Same author

Defining the optimal treatment strategy for localized prostate cancer patients: a survey of ongoing studies at the National Cancer Institute of Canada Clinical Trials Group.

Current oncology (Toronto, Ont.)·2008
Same author

Clinical experience and pre-test probability scores in the diagnosis of pulmonary embolism.

QJM : monthly journal of the Association of Physicians·2003
Same author

Use of opioid analgesics in a patient with chronic abdominal pain.

International journal of clinical practice·2002
Same author

The Canadian exercise technetium 99m-labeled teboroxime single-photon emission computed tomographic study. Canadian Exercise Teboroxime SPECT Study Investigators.

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology·1995
Same journal

Posttreatment ⁶⁸Ga-FAP-2286 PET/CT Parameters for Response and Survival Assessment After ¹⁷⁷Lu-FAP-2286 Radioligand Therapy in Advanced Solid Tumors.

Clinical nuclear medicine·2026
Same journal

18F-FDG PET/CT Imaging of Multiple Inflammatory Myofibroblastic Tumors.

Clinical nuclear medicine·2026
Same journal

Intense Incidental F-18 DOPA Uptake in Low-grade Prostate Adenocarcinoma: A Potential Diagnostic Pitfall.

Clinical nuclear medicine·2026
Same journal

A Prospective Head-to-Head Comparison of HER2-Targeted and 18F-FDG PET/CT for Detecting Axillary Lymph Node Metastases Among Newly Diagnosed HER2-Positive and HER2-Low Breast Cancer.

Clinical nuclear medicine·2026
Same journal

Epileptogenic Brain Metastasis Early Positive on 18FDG PET/CT Compared to MRI.

Clinical nuclear medicine·2026
Same journal

Dural Manifestation of Langerhans Cell Histiocytosis​: Multimodality Imaging Approach.

Clinical nuclear medicine·2026
See all related articles

Radiochemically impure Tc-99m MAA preparations were identified in two patients. The impurity, hydrolyzed-reduced technetium (TcO2), was detected, impacting imaging results.

Area of Science:

  • Nuclear medicine
  • Radiopharmaceutical chemistry
  • Medical imaging

Background:

  • Technetium-99m macroaggregated albumin (Tc-99m MAA) is a crucial radiopharmaceutical for diagnostic imaging.
  • Ensuring the radiochemical purity of Tc-99m MAA is essential for accurate diagnostic interpretation.
  • Radiochemical impurities can lead to suboptimal imaging and potentially misdiagnosis.

Observation:

  • Two separate patient cases revealed unexpected findings during diagnostic imaging.
  • These findings were associated with the administration of Tc-99m MAA radiopharmaceutical preparations.
  • Clinical imaging demonstrated the presence of a specific radiochemical impurity.

Findings:

  • The radiopharmaceutical preparations administered were found to be radiochemically impure.

Related Experiment Videos

  • The specific impurity identified was hydrolyzed-reduced technetium (TcO2).
  • The presence of TcO2 was clinically evident in the imaging findings of both patients.

    • Implications:

    • The presence of TcO2 in Tc-99m MAA can alter biodistribution and imaging characteristics.
    • This highlights the importance of rigorous quality control for radiopharmaceuticals.
    • Potential for misinterpretation of diagnostic images due to radiochemical impurities necessitates careful review of radiopharmaceutical quality.